Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin: 2013-2025

Historic FCF Margin for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to 24.62%.

  • Amphastar Pharmaceuticals' FCF Margin rose 48.00% to 24.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.66%, marking a year-over-year decrease of 786.00%. This contributed to the annual value of 23.55% for FY2024, which is 99.00% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported FCF Margin of 24.62% as of Q3 2025, which was up 71.59% from 14.35% recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' FCF Margin peaked at 36.60% during Q1 2022, and registered a low of -4.14% during Q3 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' FCF Margin averaged around 21.78%, with its median value being 24.15% (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' FCF Margin slumped by 2,807bps in 2022 and then surged by 3,357bps in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' FCF Margin (Quarterly) stood at 27.76% in 2021, then tumbled by 2,116bps to 6.60% in 2022, then surged by 149bps to 8.10% in 2023, then skyrocketed by 81bps to 8.91% in 2024, then spiked by 48bps to 24.62% in 2025.
  • Its FCF Margin stands at 24.62% for Q3 2025, versus 14.35% for Q2 2025 and 14.30% for Q1 2025.